184 related articles for article (PubMed ID: 31090264)
1. Estrogen receptor coactivator Mediator Subunit 1 (MED1) as a tissue-specific therapeutic target in breast cancer.
Leonard M; Zhang X
J Zhejiang Univ Sci B; 2019 May; 20(5):381-390. PubMed ID: 31090264
[TBL] [Abstract][Full Text] [Related]
2. HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.
Yang Y; Leonard M; Zhang Y; Zhao D; Mahmoud C; Khan S; Wang J; Lower EE; Zhang X
Cancer Res; 2018 Jan; 78(2):422-435. PubMed ID: 29187405
[TBL] [Abstract][Full Text] [Related]
3. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.
Cui J; Germer K; Wu T; Wang J; Luo J; Wang SC; Wang Q; Zhang X
Cancer Res; 2012 Nov; 72(21):5625-34. PubMed ID: 22964581
[TBL] [Abstract][Full Text] [Related]
4. Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.
Zhang L; Cui J; Leonard M; Nephew K; Li Y; Zhang X
PLoS One; 2013; 8(7):e70641. PubMed ID: 23936234
[TBL] [Abstract][Full Text] [Related]
5. Arginine and glutamate-rich 1 (ARGLU1) interacts with mediator subunit 1 (MED1) and is required for estrogen receptor-mediated gene transcription and breast cancer cell growth.
Zhang D; Jiang P; Xu Q; Zhang X
J Biol Chem; 2011 May; 286(20):17746-54. PubMed ID: 21454576
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance.
Bick G; Zhang J; Lower EE; Zhang X
Cancer Drug Resist; 2022; 5(2):498-510. PubMed ID: 35800368
[TBL] [Abstract][Full Text] [Related]
7. Essential role of MED1 in the transcriptional regulation of ER-dependent oncogenic miRNAs in breast cancer.
Nagpal N; Sharma S; Maji S; Durante G; Ferracin M; Thakur JK; Kulshreshtha R
Sci Rep; 2018 Aug; 8(1):11805. PubMed ID: 30087366
[TBL] [Abstract][Full Text] [Related]
8. Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer.
Yang Y; Leonard M; Luo Z; Yeo S; Bick G; Hao M; Cai C; Charif M; Wang J; Guan JL; Lower EE; Zhang X
Cell Rep; 2021 Mar; 34(10):108822. PubMed ID: 33691110
[TBL] [Abstract][Full Text] [Related]
9. MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription.
Zhang X; Krutchinsky A; Fukuda A; Chen W; Yamamura S; Chait BT; Roeder RG
Mol Cell; 2005 Jul; 19(1):89-100. PubMed ID: 15989967
[TBL] [Abstract][Full Text] [Related]
10. Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation.
Jiang P; Hu Q; Ito M; Meyer S; Waltz S; Khan S; Roeder RG; Zhang X
Proc Natl Acad Sci U S A; 2010 Apr; 107(15):6765-70. PubMed ID: 20351249
[TBL] [Abstract][Full Text] [Related]
11. Med1 plays a critical role in the development of tamoxifen resistance.
Nagalingam A; Tighiouart M; Ryden L; Joseph L; Landberg G; Saxena NK; Sharma D
Carcinogenesis; 2012 Apr; 33(4):918-30. PubMed ID: 22345290
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
13. Role of the Mediator Complex and MicroRNAs in Breast Cancer Etiology.
Maldonado E; Morales-Pison S; Urbina F; Jara L; Solari A
Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205279
[TBL] [Abstract][Full Text] [Related]
14. Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles.
Zhang Y; Leonard M; Shu Y; Yang Y; Shu D; Guo P; Zhang X
ACS Nano; 2017 Jan; 11(1):335-346. PubMed ID: 27966906
[TBL] [Abstract][Full Text] [Related]
15. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
[TBL] [Abstract][Full Text] [Related]
16. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
18. Roles of Estrogen Receptor-α and the Coactivator MED1 During Human Endometrial Decidualization.
Kaya Okur HS; Das A; Taylor RN; Bagchi IC; Bagchi MK
Mol Endocrinol; 2016 Mar; 30(3):302-13. PubMed ID: 26849466
[TBL] [Abstract][Full Text] [Related]
19. Mediator subunits MED1 and MED24 cooperatively contribute to pubertal mammary gland development and growth of breast carcinoma cells.
Hasegawa N; Sumitomo A; Fujita A; Aritome N; Mizuta S; Matsui K; Ishino R; Inoue K; Urahama N; Nose J; Mukohara T; Kamoshida S; Roeder RG; Ito M
Mol Cell Biol; 2012 Apr; 32(8):1483-95. PubMed ID: 22331469
[TBL] [Abstract][Full Text] [Related]
20. Cardiac Med1 deletion promotes early lethality, cardiac remodeling, and transcriptional reprogramming.
Spitler KM; Ponce JM; Oudit GY; Hall DD; Grueter CE
Am J Physiol Heart Circ Physiol; 2017 Apr; 312(4):H768-H780. PubMed ID: 28159809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
